BRPI0612268A2 - Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus - Google Patents

Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus

Info

Publication number
BRPI0612268A2
BRPI0612268A2 BRPI0612268-0A BRPI0612268A BRPI0612268A2 BR PI0612268 A2 BRPI0612268 A2 BR PI0612268A2 BR PI0612268 A BRPI0612268 A BR PI0612268A BR PI0612268 A2 BRPI0612268 A2 BR PI0612268A2
Authority
BR
Brazil
Prior art keywords
virus
influenza
producing
generating
cells
Prior art date
Application number
BRPI0612268-0A
Other languages
English (en)
Inventor
Gregory Duke
George Kemble
James Young
Zhaoti Wang
Original Assignee
Medimmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Vaccines Inc filed Critical Medimmune Vaccines Inc
Publication of BRPI0612268A2 publication Critical patent/BRPI0612268A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ÁCIDO NUCLEICO ISOLADO, VETOR DE EXPRESSçO, MÉTODOS PARA PRODUZIR UM RNA GENâMICO DA INIFLUENZA, PARA PRODUZIR UM VÍRUS DA INFLUENZA RECOMBINANTE, PARA GERAR UM VÍRUS DE RNA SEGMENTADO DE FILAMENTO NEGATIVO RECOMBINANTE NAS CÉLULAS CANINAS CULTIVADAS E PARA GERAR PARTÍCULAS VIRAIS DA INFLUENZA INFECCIOSA EM CÉLULAS CANiNAS CULTIVADAS, CÉLULA, E, VÍRUS. A presente invenção fornece novas sequências de ácido nucleico reguladoras da polimerase 1 canina, úteis para a expressão das sequências de ácido nucleico em células caninas tais como as células MDCK. A invenção ainda fornece vetores de expressão e células compreendendo tais ácidos nucleicos, bem como métodos de uso de tais ácidos nucleicos para produzir vírus da influenza, incluindo os vírus da influenza infecciosa.
BRPI0612268-0A 2005-06-21 2006-06-20 Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus BRPI0612268A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US69297805P 2005-06-21 2005-06-21
US69296505P 2005-06-21 2005-06-21
US69955505P 2005-07-15 2005-07-15
US69955605P 2005-07-15 2005-07-15
US70200605P 2005-07-22 2005-07-22
US79352506P 2006-04-19 2006-04-19
US79352206P 2006-04-19 2006-04-19
PCT/US2006/023867 WO2007002008A2 (en) 2005-06-21 2006-06-20 Methods and compositions for expressing negative-sense viral rna in canine cells

Publications (1)

Publication Number Publication Date
BRPI0612268A2 true BRPI0612268A2 (pt) 2009-01-27

Family

ID=37595721

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612268-0A BRPI0612268A2 (pt) 2005-06-21 2006-06-20 Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus

Country Status (11)

Country Link
US (4) US20060286591A1 (pt)
EP (2) EP1917352A4 (pt)
JP (2) JP2008546408A (pt)
KR (2) KR20080024212A (pt)
AU (2) AU2006262380A1 (pt)
BR (1) BRPI0612268A2 (pt)
CA (2) CA2613283A1 (pt)
IL (1) IL188202A0 (pt)
NO (1) NO20080358L (pt)
RU (1) RU2008101367A (pt)
WO (2) WO2007002008A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1917352A4 (en) 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101528941B (zh) * 2006-04-19 2014-03-12 米迪缪尼有限公司 在犬细胞中表达负义病毒rna的方法和组合物
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
US9163053B2 (en) * 2007-05-18 2015-10-20 Fluidigm Corporation Nucleotide analogs
JP5540329B2 (ja) 2007-06-26 2014-07-02 公益財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
JP5836266B2 (ja) 2009-05-21 2015-12-24 ノバルティス アーゲー 非内因性polIプロモーターを使用した逆遺伝学
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
CN102220437B (zh) * 2011-04-27 2014-04-23 贵州省烟草科学研究所 部分接种鉴定烟草病毒病抗性的方法
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
GB201220119D0 (en) * 2012-11-08 2012-12-26 Univ Cork Vector
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016148195A1 (ja) * 2015-03-17 2016-09-22 一般財団法人阪大微生物病研究会 インフルエンザウイルス作出用細胞
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN106520700B (zh) * 2016-11-10 2019-12-27 中国食品药品检定研究院 稳定表达牛胰蛋白酶原的mdck细胞系及其用途
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JPWO2020004425A1 (ja) * 2018-06-27 2021-07-08 一般財団法人阪大微生物病研究会 インフルエンザウイルスの培養方法
CN109762938B (zh) * 2019-02-01 2022-06-10 中国水产科学研究院珠江水产研究所 用于区分鳜鱼弹状病毒vRNA、cRNA和mRNA的引物组合及试剂盒
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
BR102020010208A2 (pt) 2020-05-21 2022-04-12 Fundação Oswaldo Cruz Construção de ácido nucleico, virus influenza recombinante, método para preparar um virus influenza recombinante, composição, e, uso.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US6887699B1 (en) * 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
FR2723104B1 (fr) * 1994-07-27 1996-09-13 Rhone Poulenc Rorer Sa Nouvelle topoisomerase iv, sequences nucleotiques correspondantes et leurs utilisations
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
AU694592B2 (en) 1994-11-16 1998-07-23 St. Jude Children's Research Hospital Novel replication process
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) * 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
WO1998013501A2 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
US6946291B2 (en) * 1998-04-24 2005-09-20 University Hospitals Of Cleveland Mixed cell diagnostic systems
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
AU5921101A (en) 2000-04-28 2001-11-12 St Jude Childrens Res Hospital Dna transfection system for the generation of infectious influenza virus
JP2004504026A (ja) * 2000-07-18 2004-02-12 バイエル アクチェンゲゼルシャフト ヒトdesc1様セリンプロテアーゼの調節
US20040241139A1 (en) * 2000-07-20 2004-12-02 Gerd Hobom Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement
EP3009507B1 (en) * 2002-02-13 2020-06-24 Wisconsin Alumini Research Foundation Signal for packaging of influenza virus vectors
EP1485488A4 (en) * 2002-02-21 2005-03-02 Sinai School Medicine RECOMBINANT EXPRESSION SYSTEMS FOR MINUSTRAN VIRUS RNA AND VACCINES
CN1678345B (zh) 2002-04-26 2013-09-11 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
US7132523B2 (en) * 2002-07-03 2006-11-07 Ortho-Mcneil Pharmaceutical, Inc. Human PRSS11-Like S2 serine protease and uses thereof
CA2501645A1 (en) * 2002-10-10 2004-04-22 Verenium Corporation Proteases, nucleic acids encoding them and methods for making and using them
CA2807534A1 (en) * 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
CA2421086A1 (fr) * 2003-02-28 2004-08-28 Institut Pasteur Promoteur de l'arn polymerase i de poulet et son utilisation
ES2593082T3 (es) 2003-05-28 2016-12-05 Wisconsin Alumni Research Foundation Virus de la gripe recombinantes a título elevado para vacunas y terapia génica
AU2004274860A1 (en) * 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polII promoter and ribozymes
EP1697521B1 (en) * 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
NZ556061A (en) * 2004-12-24 2009-06-26 Solvay Biologicals Bv Rescue of influenza virus
EP1917352A4 (en) 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CN101528941B (zh) * 2006-04-19 2014-03-12 米迪缪尼有限公司 在犬细胞中表达负义病毒rna的方法和组合物

Also Published As

Publication number Publication date
US20060286591A1 (en) 2006-12-21
EP1917361A2 (en) 2008-05-07
JP2008543331A (ja) 2008-12-04
WO2007002007A8 (en) 2007-05-10
US20120329150A1 (en) 2012-12-27
EP1917352A4 (en) 2009-03-25
NO20080358L (no) 2008-03-03
US8278433B2 (en) 2012-10-02
CA2613284A1 (en) 2007-01-04
WO2007002007A2 (en) 2007-01-04
WO2007002007A3 (en) 2007-06-21
KR20080025171A (ko) 2008-03-19
US20110045586A1 (en) 2011-02-24
AU2006262381A1 (en) 2007-01-04
WO2007002008A2 (en) 2007-01-04
KR20080024212A (ko) 2008-03-17
EP1917352A2 (en) 2008-05-07
WO2007002008A3 (en) 2007-12-27
IL188202A0 (en) 2008-03-20
RU2008101367A (ru) 2009-08-10
JP2008546408A (ja) 2008-12-25
CA2613283A1 (en) 2007-01-04
AU2006262380A1 (en) 2007-01-04
EP1917361A4 (en) 2009-07-29
US8742089B2 (en) 2014-06-03
US20100203641A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
ES2526191T3 (es) Método para producir virus influenza B infeccioso en cultivo celular
ATE460473T1 (de) Immortalisierte entezelllinien zur viruserzeugung
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
RU2008101367A (ru) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
ATE353370T1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
BRPI0518568A2 (pt) mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
JP2015119730A5 (pt)
MX2021000210A (es) Metodos y productos para transfeccion de celulas.
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
DE69535940D1 (de) Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
NZ609903A (en) Expression vector for high level expression of recombinant proteins
EA201791343A1 (ru) Композиции и способы для конструирования вирусного генома in vitro
NO20054124L (no) Dyre-fri celle kultur metode
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
MX387420B (es) Producción de virus en cultivos celulares.
EP1721985A4 (en) Nucleic acid construct containing full-length genome of human hepatitis c virus, recombinant full-length virus genome replicative cell having the nucleic acid construct transferred thereinto and method of constructing hepatitis c viral particles
EP1739167A4 (en) PROCESS FOR VIRUS PRODUCTION
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
EP1666598A4 (en) NUCLEIC ACID AND GEN GENES FROM A NEW HCV TRIBE, AND THE REPLICANT-REPLICATING CELL USING THE GENE
EA200500547A1 (ru) Конструкции нуклеиновых кислот для экспрессии генов
JP2013529913A5 (pt)
EA201201620A1 (ru) Способ получения рнк-вируса
WO2011074928A1 (ru) Рекомбинантный штамм a/astanarg/6:2/2009 m-12-09/d вируса гриппа, полученный методом обратной генетики из высокопатогенного штамма-донора а/сhiсkеn/аstаnа/ 6/05 (h5n1) и высокорепродуктивного штамма-донора а/рuеrtо rico/8/34 (h1n1), семейства оrthоmyхоviridае рода influеnzаvirus типа а, депонированный в коллекции микроорганизмов дгп ниипбб ргп нцб pk kh moh pk, применяемый в биотехнологии для производства диагностических и вакцинных препаратов против гриппа a/h5n1

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MEDIMMUNE, INC. (US)

Free format text: TRANSFERIDO POR INCORPORACAO DE: MEDIMMUNE VACCINES, INC.

B25D Requested change of name of applicant approved

Owner name: MEDIMMUNE, LLC (US)

Free format text: ALTERADO DE: MEDIMMUNE, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2213 DE 04/06/2013.